ATREZZO
Clinical Trial Program
A Phase II clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positive advanced/metastatic breast cancer
Phase II
Status
Recruiting
Tumour subtype:
HER2+
Scenario
Locally Advanced or Metastatic
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Aleix Prat, MD, PhD Hospital Clínic de Barcelona (Spain)
Eva Mª Ciruelos Gil , MD, PhD (Hospital 12 de Octubre, Madrid (Spain))
Sites
COMPLEJO HOSPITALARIO HOSPITAL “SAN PEDRO DE ALCANTARA”, COMPLEXO HOSPITALARIO UNIVERSITARIO A CORUÑA (HOSPITAL TERESA HERRERA), HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL DE FUENLABRADA, HOSPITAL DE LEÓN, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, HOSPITAL SON ESPASES, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO DE CANARIAS, HOSPITAL UNIVERSITARIO SAN CECILIO, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO HOSPITALET (DURAN I REYNALS)
